ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2527

Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS)

Jacques-Eric Gottenberg1, Kathy Sivils2, Kim Campbell3, Jada Idokogi3, Kim Lo3, Sophia G. Liva3, Jonathan Shelton4, Harman Dhatt5, Jonathan J. Hubbard3 and Ghaith Noaiseh6, 1Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 2Johnson & Johnson Innovative Medicine, Edmond, OK, 3Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, 4Janssen Scientific Affairs, LLC, San Diego, CA, USA, San Diego, 5Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, USA, Raritan, NJ, 6University of Kansas Medical Center, Kansas City, KS

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, clinical trial, Fc receptors, Intervention, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Plenary III

Session Type: Plenary Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by the presence of specific autoantibodies (AAb) and lymphocytic infiltration of exocrine glandular tissues. Nipocalimab, an anti-neonatal Fc receptor (FcRn) mAb, reduces circulating IgG including AAb, by selectively blocking IgG–FcRn interactions. Here, we evaluated the efficacy and safety of nipocalimab in patients (pts) with primary SjD.

Methods: A phase 2 study (DAHLIAS; NCT04968912) included adults (18-75 years) with moderately-to-severely active primary SjD (total Clinical European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index [clinESSDAI] ≥6) who were seropositive for anti-Ro60/-Ro52 IgG antibodies. Randomized pts (1:1:1) received intravenous (IV) nipocalimab 5 or 15 mg/kg, or placebo (PBO) every 2 weeks (W) through W22 and protocol-permitted background standard of care. The primary endpoint of change from baseline (BL) in clinESSDAI score at W24 was chosen to avoid mechanistic bias with IgG levels. Safety was assessed through W30.

Results: In total, 163 pts were enrolled (nipocalimab: 5 mg/kg, n=53; 15 mg/kg, n=54; PBO, n=56). BL characteristics were comparable between groups. The nipocalimab 15 mg/kg group met the primary endpoint versus (vs) PBO (least squares mean difference for 15 mg/kg: –2.65; 90% CI, –4.03, –1.28; p=0.002; for 5 mg/kg: –0.34; 90% CI, –1.71, 1.03; p=0.681; Table 1). Similar improvements in the 15 mg/kg nipocalimab group vs PBO were observed in most secondary/exploratory endpoints (Table 1), including changes from BL at W24 in Physician Global Assessment of Disease Severity and ESSDAI score, treatment response according to Sjögren’s Tool for Assessing Response, Composite of Relevant Endpoints for Sjogren’s Syndrome, and disease activity level response (decrease in ≥1 clinESSDAI domain), among others. Pt-reported outcome measures numerically improved in the 15 mg/kg nipocalimab group vs PBO. Efficacy outcomes in the 5 mg/kg nipocalimab group were generally similar to PBO. Serious adverse events were reported in 7.5%, 7.4%, and 5.4% of participants with nipocalimab 5 mg/kg, 15 mg/kg, and PBO, respectively (Table 2). Significant nipocalimab dose-dependent reductions in IgG and AAb were observed. Severe infections/infections requiring IV anti-infectives occurred in 3.8%, 1.9%, and 1.8% of patients, respectively, without a clear correlation with IgG nadir; none were related to study treatment. At W24, changes from BL in albumin, low-density lipoprotein cholesterol, and total cholesterol were reported at –6.9%, 6.6%, and 8.3%, respectively. No opportunistic infections/severe hypoalbuminemia/deaths were reported.

Conclusion: DAHLIAS, the first study of a FcRn blocker in SjD, showed that nipocalimab led to significant improvement vs PBO in clinESSDAI and similar trends in other key efficacy endpoints at W24, and is well-tolerated. These results demonstrate the mechanistic relevance of FcRn inhibition in SjD, indicating the potential pathogenicity of IgG AAb. These findings establish proof of concept for nipocalimab in SjD and support further evaluation in pts with moderate-to-severe AAb-positive SjD.

Supporting image 1

Table 1. Primary Endpoint, Key Supportive and Secondary Endpoints at Week 24

Supporting image 2

Table 2. Number of Participants With Treatment-Emergent Adverse Events


Disclosures: J. Gottenberg: AbbVie, 2, BMS, 2, 5, Galapagos, 2, Gilead, 2, Lilly, 2, MSD, 2, Novartis, 2, Pfizer, 2, 5; K. Sivils: Janssen Research & Development, LLC, 3, Johnson & Johnson, 11; K. Campbell: Janssen Research & Development, LLC, 3, Johnson & Johnson, 11; J. Idokogi: Janssen Research & Development, LLC, 3, Johnson & Johnson, 11; K. Lo: Janssen Research & Development, LLC, 3, Johnson & Johnson, 11; S. Liva: Janssen Research & Development, LLC, 3, Johnson and Johnson, 11; J. Shelton: Janssen, 3, Johnson & Johnson, 11; H. Dhatt: Janssen, 3, Johnson & Johnson, 11; J. Hubbard: Janssen Research & Development, LLC, 3, Johnson & Johnson, 11; G. Noaiseh: Janssen, 1, Novartis, 1.

To cite this abstract in AMA style:

Gottenberg J, Sivils K, Campbell K, Idokogi J, Lo K, Liva S, Shelton J, Dhatt H, Hubbard J, Noaiseh G. Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/efficacy-and-safety-of-nipocalimab-an-anti-fcrn-monoclonal-antibody-in-primary-sjogrens-disease-results-from-a-phase-2-multicenter-randomized-placebo-controlled-double-blind-study-dah/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-nipocalimab-an-anti-fcrn-monoclonal-antibody-in-primary-sjogrens-disease-results-from-a-phase-2-multicenter-randomized-placebo-controlled-double-blind-study-dah/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology